Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Management expressed optimism about resuming sales in France following a successful remediation plan ... has the potential to outshine industry giants like Novo Nordisk and Eli Lilly. Allurion’s ...

Global stocks mostly rose Thursday on easing trade tensions, with London and Frankfurt hitting record highs ahead of key US ...

Basel: Roche has announced that Wafaa Mamilli will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker, and will become a member of the ...

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

Please note: we will be discontinuing the Global Markets Report after 28 February. Australian shares are set to open lower, ...